The tumor-promoting activities of the PRKACA and PKA signaling have been described for classic and fibrolamellar variants of hepatocellular carcinoma, and breast, prostate, ovarian, and non-small cell lung cancers, glioblastoma, astrocytoma, and leukemia [11,12,13,14,15]. This evidence concerns the gene PRKACA and leukemia.